ASCO 2019 - Kantar reviews results from phase 3 POLO trial

Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based on a biomarker (gBRCA mt) in first-line metastatic disease. Anna Boudoures from Kantar reviews the "practice-changing" results of the phase 3 POLO trial of AstraZeneca and Merck & Co's drug, as presented at ASCO 2019 in Chicago. [video width="1280" height="720" mp4="https://pharmaphorum.com/wp-content/uploads/2019/06/Kantar-Vlog-3-03_06_2019-1.mp4"][/video]   Click here to view exclusive live coverage from ASCO 2019.